): The objective of the proposed project is to demonstrate the efficacy of a living irradiated polyvalent melanoma cell vaccine (PMCV) in a Phase III multicenter clinical trial examining AJCC Stage IV melanoma patients rendered clinically free of disease by surgery. This project's specific aims are: 1. Conduct a multicenter randomized double-blind Phase III trial of PMCV plus BCG versus placebo plus BCG as adjuvant immunotherapy in AJCC Stage IV melanoma patients rendered clinically free of disease (no evidence of disease (NED)) by surgical resection. 2. Determine the clinical results in a multicenter trial of surgical resection of distant metastases in Stage IV melanoma. 3. Determine whether new immunological and molecular markers can be used to detect subclinical metastatic melanoma and evaluate the response to adjuvant therapy. We hypothesize that these new techniques can be used as prognostic factors in predicting the outcome of adjuvant therapy for melanoma patients following surgery. Methodology to accurately identify patients with subclinical tumor burden would be very useful as stratification factors in clinical trials of adjuvant therapy, as well as in the management of the individual melanoma patient. 4. Develop methods to evaluate immunogenicity and monitor responses to PMCV by detecting antibody responses to active immunotherapy against specific melanoma-associated antigens and the induction of skin test responses to PMCV. Determine whether there is any correlation between such responses and the clinical course of vaccine patients in a prospective multicenter trial.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA076489-01A1
Application #
2692077
Study Section
Special Emphasis Panel (ZCA1-GRB-Z (M1))
Program Officer
Wu, Roy S
Project Start
1998-09-10
Project End
2003-06-30
Budget Start
1998-09-10
Budget End
1999-06-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Slingluff Jr, Craig L; Petroni, Gina R; Olson, Walter C et al. (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036-44
Faries, Mark B; Hsueh, Eddy C; Ye, Xing et al. (2009) Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 15:7029-35
Torisu-Itakura, Hitoe; Lee, Jonathan H; Huynh, Young et al. (2007) Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother 30:831-8
Terando, Alicia M; Faries, Mark B; Morton, Donald L (2007) Vaccine therapy for melanoma: current status and future directions. Vaccine 25 Suppl 2:B4-16
Faries, Mark B (2006) Evaluation of immunotherapy in the treatment of melanoma. Surg Oncol Clin N Am 15:399-418
Faries, Mark B; Morton, Donald L (2006) The promise of metastasectomy in melanoma. Ann Surg Oncol 13:607-9
Morton, Donald L (2005) Immunotherapy today: the story of a vaccine. J Drugs Dermatol 4:672-6
Faries, Mark B; Morton, Donald L (2005) Therapeutic vaccines for melanoma: current status. BioDrugs 19:247-60
Hsueh, Eddy C; Essner, Richard; Foshag, Leland J et al. (2004) Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 100:122-9
Hsueh, Eddy C; Famatiga, Estela; Shu, Sherry et al. (2004) Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol 11:892-9

Showing the most recent 10 out of 14 publications